Clinical Trial Update: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) [Phase 2]

View source ↗

Summary

This clinical trial update notes that the Phase 2 HPTN 102 study evaluating lenacapavir in combination with emtricitabine/tenofovir disoproxil fumarate for HIV …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/Tenofovir disoproxil fumarate (emtricitabine/tenofovir disoproxil fumarate)
• Lenacapavir (lenacapavir)

Snippet

Sponsor: Gilead Sciences | Conditions: Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Status: ACTIVE_NOT_RECRUITING